Grünenthal Group

Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:22:04 CET | Grünenthal GroupPress release

Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.
EG Danmark A/S

EG opkøber to softwarevirksomheder fra Tieto og udvider sin position inden for uddannelse og offentlig HR- & lønadministration i Norden18.2.2026 09:07:52 CET | EG Danmark A/SPressemeddelelse

EG har indgået aftale om at opkøbe to softwarevirksomheder fra Tieto og går dermed ind på det svenske og finske uddannelsesmarked samt det svenske marked for HR & lønadministration. Transaktionen omfatter cirka 260 medarbejdere og to softwarevirksomheder med stærke markedspositioner inden for uddannelse og offentlig HR & lønadministration i Sverige og Finland, med en samlet årlig omsætning på cirka 278 millioner kroner.
LEO Pharma

LEO Pharma delivers 10% revenue growth in 2025 and more than doubles adjusted EBITDA margin18.2.2026 09:00:00 CET | LEO PharmaPressemeddelelse

Ballerup, Denmark, 18 February, 2026 – In 2025, LEO Pharma delivered a third consecutive year of double‑digit revenue growth (CER), at the upper end of guidance, and achieved a significant improvement in profitability, returning to positive net profit and free cash flow. The portfolio was strengthened by the launch of Anzupgo® in 10 additional markets, including the U.S., as well as the addition of Spevigo®. The pipeline was advanced through new late‑stage programs and strategic partnerships aimed at accelerating innovation. For 2026, revenue growth is expected to be 8-11% (CER), supporting further improvement in the adjusted EBITDA margin to 16-19%, alongside increased investments in innovation and LEO Pharma’s global platform. Financial highlights LEO Pharma’s revenue increased by 10% at constant exchange rates (CER) and by 8% in DKK to 13,499 million. Revenue growth was led by North America (+35% at CER), with Rest of World (+9% at CER) and Europe (+3% at CER) also contributing to t
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sidste
  • >>
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye